<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="8" ids="10033">Warfarin</z:chebi> is a common <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> with narrow therapeutic window and variable anticoagulation effects </plain></SENT>
<SENT sid="1" pm="."><plain>Single gene polymorphisms in <z:chebi fb="0" ids="38559">cytochrome P450</z:chebi> 2C9 (CYP2C9) and <z:chebi fb="0" ids="28371">vitamin K epoxide</z:chebi> reductase (VKORC1) have been shown to impact <z:chebi fb="8" ids="10033">warfarin</z:chebi> dosing in adults </plain></SENT>
<SENT sid="2" pm="."><plain>Insufficient data exists on genetic and clinical factors which influence <z:chebi fb="8" ids="10033">warfarin</z:chebi> dosing in children </plain></SENT>
<SENT sid="3" pm="."><plain>Pediatric patients with <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> who received long-term <z:chebi fb="8" ids="10033">warfarin</z:chebi> therapy were tested for VKORC1 and CYP2C9 polymorphisms </plain></SENT>
<SENT sid="4" pm="."><plain>Clinical and demographic data were reviewed in those children who achieved stable therapeutic international normalized ratio (INR) </plain></SENT>
<SENT sid="5" pm="."><plain>Multiple linear regression modeling was used to assess relationships between stable <z:chebi fb="8" ids="10033">warfarin</z:chebi> doses and genetic or clinical variables </plain></SENT>
<SENT sid="6" pm="."><plain>Fifty children were tested for VKORC1 and CYP2C9 polymorphisms; 37 patients (M 26: F 11) had complete data, achieved stable therapeutic INR, and were included in dose variability analysis </plain></SENT>
<SENT sid="7" pm="."><plain>There were predominance of white race 73% and male sex 70.3% </plain></SENT>
<SENT sid="8" pm="."><plain>The mean age was 9.6 years (1.8-18.6 years) </plain></SENT>
<SENT sid="9" pm="."><plain>The mean weight was 37.8 kg (7.7-95 kg) </plain></SENT>
<SENT sid="10" pm="."><plain>Fontan <z:mp ids='MP_0001532'>physiology</z:mp> and mechanical cardiac valves were two most common indications for <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:chebi fb="8" ids="10033">warfarin</z:chebi> therapy (25/37 or 67.6%) </plain></SENT>
<SENT sid="11" pm="."><plain>Twelve patients (32.4%) had â‰¥ 2 indications for <z:chebi fb="8" ids="10033">warfarin</z:chebi> therapy </plain></SENT>
<SENT sid="12" pm="."><plain>Three patients had documented venous or arterial clots, and 5 patients had <z:hpo ids='HP_0001297'>strokes</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain><z:hpo ids='HP_0002564'>Congenital heart disease</z:hpo> was present in 29 patients (78.4%), including Fontan <z:mp ids='MP_0001532'>physiology</z:mp> (20), complex biventricular <z:mp ids='MP_0001532'>physiology</z:mp> (4), and congenital <z:e sem="disease" ids="C0264765,C0026265" disease_type="Disease or Syndrome" abbrv="">mitral valve disease</z:e> (5) </plain></SENT>
<SENT sid="14" pm="."><plain>Acquired <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> was present in 8 patients (21.6%), including <z:e sem="disease" ids="C0026691" disease_type="Disease or Syndrome" abbrv="MLNS|MCLS">Kawasaki disease</z:e> with coronary <z:hpo ids='HP_0002617'>aneurysms</z:hpo> (3), acquired <z:e sem="disease" ids="C0264765,C0026265" disease_type="Disease or Syndrome" abbrv="">mitral valve disease</z:e> (3), and <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> (2) </plain></SENT>
<SENT sid="15" pm="."><plain>Stable <z:chebi fb="8" ids="10033">warfarin</z:chebi> dose (mg/kg/day) was strongly associated with VKORC1 polymorphism (p &lt; 0.0001) and goal therapeutic INR (p = 0.009) </plain></SENT>
<SENT sid="16" pm="."><plain>Negative correlations were observed between stable <z:chebi fb="8" ids="10033">warfarin</z:chebi> dose and age, weight, height, and BSA (p = 0.04, 0.02, 0.02, and 0.02 respectively) </plain></SENT>
<SENT sid="17" pm="."><plain>Factors which did not influence <z:chebi fb="8" ids="10033">warfarin</z:chebi> dose included CYP2C9 polymorphism (p = 0.17), concurrent medications (p = 0.85), sex (p = 0.4), race (p = 0.14), <z:hpo ids='HP_0002564'>congenital heart disease</z:hpo> (p = 0.09), and Fontan <z:mp ids='MP_0001532'>physiology</z:mp> (p = 0.76) </plain></SENT>
<SENT sid="18" pm="."><plain>The gene-dose effect was observed in children with homozygous <z:mp ids='MP_0002169'>wild type</z:mp> VKORC1 CC, who required higher <z:chebi fb="8" ids="10033">warfarin</z:chebi> dose compared to those carrying heterozygous TC or homozygous TT (p = 0.028 and 0.0004 respectively) </plain></SENT>
<SENT sid="19" pm="."><plain>The full multiple linear regression model revealed that VKORC1 genotypes accounted for 47% of dosing variability; CYPC29 accounted for 5% </plain></SENT>
<SENT sid="20" pm="."><plain>Overall, the combination of VKORC1, CYP2C9, age, and target INR accounted for 82% of dosing variability </plain></SENT>
<SENT sid="21" pm="."><plain>In children with <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e>, VKORC1 genotypes, age, and target INR are important determinants influencing <z:chebi fb="8" ids="10033">warfarin</z:chebi> dosing in children with <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> </plain></SENT>
<SENT sid="22" pm="."><plain>Future <z:chebi fb="8" ids="10033">warfarin</z:chebi> dosing algorithm in children should factor both genetic and clinical factors </plain></SENT>
</text></document>